We read with interest the recent article by Fan et al.
We read with interest the recent article by Fan et al. (1) reanalyzing our review (2) published 5 years ago. Many players in the bioinformatics field criticized our study because we used a prediction rule considered too "simple." We are glad to see that the use of more complex rules only minimally affected the prediction accuracy.
The main objective of our study was to put a nail in the coffin of the custom application of inadequate validation procedures, which consisted in playing with the analytical mode on a training-test pair of data sets until the result was considered good enough for publication. We are not convinced that this plague has been eradicated in 2010. In our view, a priori specification of the methods used to divide the data and determine the gene signature, that is, the selection of the genes, prediction rule, and cutoffs (3), was and is a valid approach for hypothesis-driven research and, in this case, leads to the generalizability of prediction accuracy estimates for future patients. In contrast, trying several alternative methods and choosing the most optimal among them was and still is a good way to generate false-positive results or to support unduly optimistic views.
One major conclusion of the new reanalysis is that 6 of 7 data sets yielded a prediction accuracy in the training set that was better than chance. Of note, the data set with the strongest signal compared with a null data set (as measured by Cohen's d statistic, Fig. 4 ) was the breast cancer data set, which was actually the one for which we also found the highest prediction accuracy and the only one that passed our multiple random validation strategy with flying colors (2) . Today, that is 5 years later, it is the only one from the 7 studies that has stood the test of time in 2 subsequent independent validation studies (4). 
